All In Biotech

NDA 020771 · Upjohn

Detrol

Tolterodine Tartrate · Oral

Novel

Last checked: Nov 19, 2026Latest source record: Jul 28, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Mar 25, 1998

Approved uses

2

Original approval plus efficacy supplements

Registered trials

110

33 Phase 3, 3 recruiting

FAERS reports

8,980

5,709 serious, 551 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 15, 2023.

INDICATIONS AND USAGE DETROL Tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • DETROL · TOLTERODINE TARTRATE 1MG · TABLET, ORAL · Prescription · TE AB
  • DETROL · TOLTERODINE TARTRATE 2MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Tolterodine" as an intervention, any sponsor and status, largest first.

All 110 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective882
  • fatigue586
  • fall580
  • nausea532
  • dizziness466
  • headache449
  • asthenia437
  • diarrhoea416
  • pain401
  • urinary tract infection377
  • dyspnoea375
  • constipation322

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004383
2005519
2006455
2007369
2008408
2009420
2010600
2011474
2012537
2013294
2014498
2015465
2016488
2017454
2018446
2019481
2020373
2021267
2022276
2023184
2024249
2025202
2026136

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Detrol (Tolterodine Tartrate)

2024 spending

$84K

Beneficiaries

35

94 claims

Per beneficiary

$2,389

$7.48 per unit

View as table
YearSpending
2020$233,230
2021$200,690
2022$83,300
2023$98,513
2024$83,602

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 373 on PubMed

Sponsor: Upjohn

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.